UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes

Leukemia, 2016-03, Vol.30 (3), p.666-673

2016

Volltextzugriff (PDF)

Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia

Leukemia, 2010-04, Vol.24 (4), p.699-705

2010

Volltextzugriff (PDF)

Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia

Leukemia research, 2012-10, Vol.36 (10), p.1283-1289

2012

Volltextzugriff (PDF)

Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858

Leukemia, 2017-10, Vol.31 (10), p.2172-2180

2017

Volltextzugriff (PDF)

Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium

Leukemia, 2017-06, Vol.31 (6), p.1391-1397

2017

Volltextzugriff (PDF)

5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation

Bone marrow transplantation (Basingstoke), 2010-02, Vol.45 (2), p.255-260

2010

Volltextzugriff (PDF)

Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion

Oncogene, 2013-02, Vol.32 (9), p.1110-1120

2013

Volltextzugriff (PDF)

A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia

Leukemia, 2011-12, Vol.25 (12), p.1808-1814

2011

Volltextzugriff (PDF)

Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia

Haematologica (Roma), 2015-09, Vol.100 (9), p.1172-1179

2015

Volltextzugriff (PDF)

84 NOVEL MUTATIONS OF ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MIGHT BE ASSOCIATED WITH ADVANCE DISEASE IN MYELODYSPLASIA RELATED MYELOID NEOPLASM - ONE CENTER STUDY

Leukemia research, 2015-04, Vol.39, p.S41-S41

2015

Volltextzugriff (PDF)

Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia

Haematologica (Roma), 2016-08, Vol.101 (8), p.e320-e323

2016

Volltextzugriff (PDF)

P587: COVALENT‐101: A PHASE 1 STUDY OF BMF‐219, A NOVEL ORAL IRREVERSIBLE MENIN INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIA, DIFFUSE LARGE B‐CELL LYMPHOMA, AND MULTIPLE MYELOMA

HemaSphere, 2022-06, Vol.6, p.486-487

2022

Volltextzugriff (PDF)

P755: HYPERFERRITINEMIA IS A PREDICTIVE BIOMARKER OF POOR CLINICAL OUTCOMES IN CMML

HemaSphere, 2022-06, Vol.6, p.650-651

2022

Volltextzugriff (PDF)

Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients with Refractory Multiple Myeloma

Clinical cancer research, 2004-01, Vol.10 (1), p.88-95

2004

Volltextzugriff (PDF)

Prognostic Significance of Serial Molecular Annotation in Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (SAML)

Leukemia research, 2017-04, Vol.55, p.S10-S10

2017

Volltextzugriff (PDF)

P1073: MUTATIONAL LANDSCAPE AND CLINICAL OUTCOMES OF PATIENTS WITH MYELOID AND LYMPHOID NEOPLASMS WITH EOSINOPHILIA (MLN‐EOS) AND ABNORMALITIES OF PDGFRA, PDGFRB, FGFR1, FLT3 AND JAK REARRANGEMENT

HemaSphere, 2022-06, Vol.6 (Suppl), p.963-964

2022

Volltextzugriff (PDF)

Treatment of deletion 5q acute myeloid leukemia with lenalidomide

Leukemia, 2007-03, Vol.21 (3), p.586-588

2007

Volltextzugriff (PDF)

P-130 Reticulin fibrosis in disease progression and overall survival of chronic myelomonocytic leukemia: An independent prognostic factor?

Leukemia research, 2013-05, Vol.37, p.S82-S82

2013

Volltextzugriff (PDF)

286 THE NOVEL FC-ENGINEERED CD33 ANTIBODY BI 836858 IMPROVES HEMATOPOIESIS BY PROTECTING HSC/HPC FROM ROS-MEDIATED DNA DAMAGE IN MDS

Leukemia research, 2015-04, Vol.39, p.S142-S143

2015

Volltextzugriff (PDF)

320 RISK STRATIFICATION OF THERAPY-RELATED MYELODYSPLASTIC SYNDROMES (T-MDS): A REPORT ON BEHALF OF THE MDS CLINICAL RESEARCH CONSORTIUM

Leukemia research, 2015-04, Vol.39, p.S158-S159

2015

Volltextzugriff (PDF)

Immunosuppressive Therapy: Exploring An Underutilized Treatment Option For MDS

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.S49-S49

2015

Volltextzugriff (PDF)

Current status of clinical trials of farnesyltransferase inhibitors

Current opinion in oncology, 2001-11, Vol.13 (6), p.470-476

2001

Volltextzugriff (PDF)

Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia

Haematologica (Roma), 2013-01, Vol.98 (1), p.119-128

2013

Volltextzugriff (PDF)

Autotransplantation for relapsed or refractory Hodgkin's disease : long-term follow-up and analysis of prognostic factors

Bone marrow transplantation (Basingstoke), 1998-08, Vol.22 (3), p.265-271

1998

Volltextzugriff (PDF)

1 – 25 von 828

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(672)
Mit Volltextzugriff
(689)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(83)
The Lancet
(70)
Lancet
(28)
Journal Of Clinical Oncology
(26)
American Journal Of Human Genetics
(22)
Genetics In Medicine
(20)
Leukemia Research
(14)
Journal Of The National Comprehensive Cancer Network
(12)
The New England Journal Of Medicine
(11)
Nature
(10)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes

Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia

Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia

Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858

Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium

5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation

Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion

A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia

Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia

84 NOVEL MUTATIONS OF ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MIGHT BE ASSOCIATED WITH ADVANCE DISEASE IN MYELODYSPLASIA RELATED MYELOID NEOPLASM - ONE CENTER STUDY

Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

P587: COVALENT‐101: A PHASE 1 STUDY OF BMF‐219, A NOVEL ORAL IRREVERSIBLE MENIN INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIA, DIFFUSE LARGE B‐CELL LYMPHOMA, AND MULTIPLE MYELOMA

P755: HYPERFERRITINEMIA IS A PREDICTIVE BIOMARKER OF POOR CLINICAL OUTCOMES IN CMML

Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients with Refractory Multiple Myeloma

Prognostic Significance of Serial Molecular Annotation in Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (SAML)

P1073: MUTATIONAL LANDSCAPE AND CLINICAL OUTCOMES OF PATIENTS WITH MYELOID AND LYMPHOID NEOPLASMS WITH EOSINOPHILIA (MLN‐EOS) AND ABNORMALITIES OF PDGFRA, PDGFRB, FGFR1, FLT3 AND JAK REARRANGEMENT

Treatment of deletion 5q acute myeloid leukemia with lenalidomide

P-130 Reticulin fibrosis in disease progression and overall survival of chronic myelomonocytic leukemia: An independent prognostic factor?

286 THE NOVEL FC-ENGINEERED CD33 ANTIBODY BI 836858 IMPROVES HEMATOPOIESIS BY PROTECTING HSC/HPC FROM ROS-MEDIATED DNA DAMAGE IN MDS

320 RISK STRATIFICATION OF THERAPY-RELATED MYELODYSPLASTIC SYNDROMES (T-MDS): A REPORT ON BEHALF OF THE MDS CLINICAL RESEARCH CONSORTIUM

Immunosuppressive Therapy: Exploring An Underutilized Treatment Option For MDS

Current status of clinical trials of farnesyltransferase inhibitors

Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia

Autotransplantation for relapsed or refractory Hodgkin's disease : long-term follow-up and analysis of prognostic factors

Suchergebnisse filtern